Status:

COMPLETED

A Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal Haemoglobinuria

Lead Sponsor:

Samsung Bioepis Co., Ltd.

Conditions:

Paroxysmal Nocturnal Hemoglobinuria

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This is a randomised Phase III, double-blind, multicentre, cross-over study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB12 and Soliris® in subjects with PNH.

Detailed Description

Subjects will be randomised in a 1:1 ratio to either treatment sequence. Subjects randomly assigned to treatment with SB12 or Soliris® will receive 600 mg of eculizumab IV every week for first 4 weeks...

Eligibility Criteria

Inclusion

  • Male or female aged 18 or older
  • Eculizumab-naïve patients with PNH
  • Presence of the PNH white blood cell (WBC) clone ≥ 10%
  • Documented LDH level ≥ 1.5 x ULN at Screening
  • History of transfusion for anaemia within 12 months prior to Screening or having PNH-related symptoms at Screening
  • Subjects must be vaccinated against Neisseria meningitides

Exclusion

  • Previous treatment with any complement pathway inhibitors
  • ANC ≤ 500/mm3 or Platelet count \< 70,000/mm3
  • History of meningococcal disease
  • History of bone marrow transplantation
  • Known or suspected active bacterial/viral/fungal infection within 30 days
  • Stable use of erythropoietic, corticosteroids, heparin, warfarin before randomisation

Key Trial Info

Start Date :

August 7 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 21 2021

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT04058158

Start Date

August 7 2019

End Date

October 21 2021

Last Update

March 26 2024

Active Locations (27)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 7 (27 locations)

1

Fortis Memorial Research Institute

Gurgaon, Haryana, India, 122002

2

Post Graduate Institute of Medical Education and Research (PGIMER)

Chandigarh, India

3

Apollo Hospitals International Limited

Chennai, India

4

Amrita Institute of Medical Sciences and Research Centre

Kochi, India